Abstract
A series of hybrids of hydroxypyridinone and coumarin were rationally designed, synthesized and biologically evaluated for their iron ion chelating and MAO-B inhibitory activities. Most of the compounds displayed excellent iron ion chelating effects and moderate to good anti-MAO-B activities. Compound 27a exhibited the most potent activity against MAO-B, with an IC50 value of 14.7 nM. Importantly, 27a showed good U251 cell protective effect and significantly ameliorated the cognitive dysfunction of scopolamine-induced AD mice. Moreover, molecular docking was performed to elucidate the probable ligand-receptor interaction, and the structure-activity relationships were also summarized.
Keywords:
Alzheimer's disease; Coumarin derivatives; Hydroxypyridinones; Iron ion chelator; MAO-B inhibitor.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.
MeSH terms
-
Alzheimer Disease / chemically induced
-
Alzheimer Disease / drug therapy*
-
Alzheimer Disease / metabolism
-
Animals
-
Cell Line, Tumor
-
Cell Survival / drug effects
-
Coumarins / chemistry
-
Coumarins / pharmacology*
-
Dose-Response Relationship, Drug
-
Drug Design
-
Humans
-
Hydrogen Peroxide / antagonists & inhibitors
-
Hydrogen Peroxide / pharmacology
-
Iron Chelating Agents / chemical synthesis
-
Iron Chelating Agents / chemistry
-
Iron Chelating Agents / pharmacology*
-
Mice
-
Mice, Inbred ICR
-
Molecular Docking Simulation
-
Molecular Structure
-
Monoamine Oxidase / metabolism*
-
Monoamine Oxidase Inhibitors / chemical synthesis
-
Monoamine Oxidase Inhibitors / chemistry
-
Monoamine Oxidase Inhibitors / pharmacology*
-
Pyridines / chemistry
-
Pyridines / pharmacology*
-
Scopolamine
-
Structure-Activity Relationship
Substances
-
Coumarins
-
Iron Chelating Agents
-
Monoamine Oxidase Inhibitors
-
Pyridines
-
hydroxypyridines
-
coumarin
-
Hydrogen Peroxide
-
Scopolamine
-
Monoamine Oxidase